echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The National Food and Drug Administration approves the listing of new drugs for early targeted therapy of lung cancer

    The National Food and Drug Administration approves the listing of new drugs for early targeted therapy of lung cancer

    • Last Update: 2021-04-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The approval of the National Medical Products Administration is based on the positive results of the global Phase III registered clinical study ADAURA.


    "According to the ADAURA Phase III clinical study, osimertinib reduces the risk of disease recurrence or death by 80%, and it is expected to benefit more lung cancer patients.


    ADAURA is a randomized, double-blind, placebo-controlled global phase III clinical study, enrolling 682 patients with IB, II, and IIIA EGFRm non-small cell lung cancer who received adjuvant therapy.


    The results of the ADAURA study showed that adjuvant osimertinib can reduce the risk of DFS disease recurrence or death in patients with phase II and IIIA, the primary endpoint of the study, by 83%.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.